Adaptive Biotechnologies Corp (ADPT)

Insider Trading Filed: 2026-04-24

Key Insights

• Julie Rubinstein, President and COO of ADPT, executed a systematic net selling program over three consecutive days (04/22-04/24/2026), selling 57,180 shares total while acquiring 44,166 shares through option exercises, resulting in a net reduction of ~13,000 shares and decreased beneficial ownership from 409,868 to 382,132 shares.
• All transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 18, 2025, indicating this was a planned, legally compliant divestment strategy rather than a reactive trade based on material non-public information.
• The selling prices ($13.74-$14.44 range) were significantly higher than the option exercise price of $8.46, suggesting the executive is realizing substantial gains on previously granted equity compensation while reducing overall exposure to the company.
• The executive retained approximately 382,132 shares of common stock and 60,438 vested stock options post-transaction, maintaining a substantial ownership position that indicates continued confidence despite the net selling activity.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-21

Key Insights

• Julie Rubinstein, President and COO, executed a systematic stock sale program under a Rule 10b5-1 trading plan adopted in November 2025, selling approximately 69,061 shares across three trading days (April 17, 20, 21) at prices ranging from $14.18 to $15.13, totaling roughly $1 million in proceeds.
• Concurrent with stock sales, Rubinstein exercised stock options totaling 56,047 shares at prices of $8.46 and $12.14, suggesting a net reduction in her beneficial ownership from 422,882 shares to 395,146 shares after all transactions.
• The pre-planned nature of these transactions (10b5-1 trading plan) indicates these are routine, director-approved equity diversifications rather than concerning insider selling signals, mitigating typical negative sentiment associated with executive share sales.
• Rubinstein's remaining beneficial ownership of 395,146 common shares demonstrates maintained significant stake in the company despite the sales, suggesting continued confidence in ADPT's long-term prospects.

Sentiment: Neutral Significance: 3/10

View Original Filing →

Insider Trading Filed: 2026-04-16

Key Insights

• The reporting person, Julie Rubinstein, who is the President and COO of Adaptive Biotechnologies Corp, exercised stock options and sold shares on multiple dates in April 2026.
• The stock option exercises and share sales were done pursuant to a Rule 10b5-1 trading plan, indicating pre-planned transactions rather than discretionary trading.
• The reported transactions suggest the insider is actively managing their position in the company, potentially for liquidity or diversification purposes.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-04-13

Key Insights

• The reporting person, Julie Rubinstein, who is the President and COO of Adaptive Biotechnologies Corp, has engaged in multiple insider transactions over the past few days, including exercising stock options and selling shares.
• The reported transactions were made pursuant to a pre-arranged 10b5-1 trading plan, suggesting they were part of a planned strategy rather than ad-hoc decisions.
• The sale prices of the shares ranged from $12.75 to $14.44, with the majority of shares sold in the $12-$13 range, potentially indicating Rubinstein's view on the current fair value of the stock.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-10

Key Insights

• The reporting person, Francis Lo, exercised stock options for 2,344 shares of Adaptive Biotechnologies Corp (ADPT) and subsequently sold 22,564 shares, indicating an ongoing pattern of insider selling.
• The sale of shares was executed pursuant to a Rule 10b5-1 trading plan, suggesting a pre-planned nature of the transactions.
• The reporting person also holds an indirect beneficial ownership of 2,500 shares through his spouse, You Jin Lee, providing additional context on the insider's overall position in the company.

Sentiment: Negative Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-10

Key Insights

• The reporting person, Harlan S. Robins, who is the Chief Scientific Officer, sold 10,000 shares of Adaptive Biotechnologies Corp (ADPT) stock on 04/08/2026 at a weighted-average price of $14.85.
• The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 08/11/2025, indicating pre-planned insider selling activity.
• Following the reported transaction, the reporting person still holds 1,512,058 shares of Adaptive Biotechnologies Corp, maintaining a significant ownership stake in the company.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-08

Key Insights

• Chad M. Robins, the CEO and Chairman of Adaptive Biotechnologies Corp, reported significant insider selling of 83,332 shares on April 6, 2026 and 37,263 shares on April 8, 2026, at weighted average prices of $14.41 and $15.19 respectively.
• The insider selling appears to be part of a pre-planned 10b5-1 trading plan, which may indicate that Robins is taking some chips off the table, but is not necessarily a bearish signal.
• Investors should monitor if this insider selling activity continues in the coming quarters, as it could signal a potential shift in management's confidence or outlook for the company's future performance.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-08

Key Insights

• The reporting person, Julie Rubinstein, is the President and COO of Adaptive Biotechnologies Corp, indicating she holds a senior leadership position in the company.
• Rubinstein has exercised stock options and sold a portion of the acquired shares over a 3-day period, suggesting some insider selling activity.
• The sales were executed pursuant to a Rule 10b5-1 trading plan, potentially indicating pre-planned portfolio rebalancing rather than a bearish view on the company.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-03-26

Key Insights

• The reporting person, Julie Rubinstein (President and COO), has engaged in a series of transactions involving the exercise and sale of stock options in Adaptive Biotechnologies Corporation (ADPT).
• Over the past three trading days, Rubinstein has exercised a total of 44,166 stock options and subsequently sold 57,180 shares of common stock at weighted average prices ranging from $13.70 to $14.27.
• The transactions were made pursuant to a pre-arranged 10b5-1 trading plan, indicating a systematic approach to managing Rubinstein's equity position in the company.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-23

Key Insights

• The reporting person, Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed a series of stock option exercises and sales over the past few trading days, indicating ongoing insider liquidity activity.
• Rubinstein exercised a total of 44,166 stock options with strike prices of $6.55 and $7.27, and subsequently sold 57,180 shares in the open market at weighted average prices ranging from $13.18 to $13.83.
• The insider selling appears to be part of a Rule 10b5-1 trading plan established in November 2025, suggesting a pre-planned and non-discretionary nature to the transactions.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-02-06

Key Insights

• Insider Kyle Piskel, the Chief Financial Officer, exercised 2,145 stock options and sold 2,145 shares of Adaptive Biotechnologies Corp (ADPT) on February 4, 2026, indicating ongoing insider trading activity.
• The transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025, suggesting a pre-planned trading strategy.
• The reported transactions represent a small portion of Piskel's overall beneficial ownership, which remains at 216,637 shares, indicating he still maintains a significant stake in the company.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Current Report Filed: 2026-02-05

Key Insights

• Adaptive Biotechnologies reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's recent performance.
• The company's press release indicates that key financial metrics, such as revenue and profitability, will be an important focus for investors to assess the company's progress.
• Investors should pay close attention to any commentary or guidance provided by the company regarding its future outlook and growth prospects.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-14

Key Insights

• The reporting person, Kyle Piskel, who is the Chief Financial Officer of Adaptive Biotechnologies Corporation (ADPT), exercised 4,290 stock options and sold 4,290 shares of common stock on January 12, 2026.
• Piskel exercised the options at $12.14 per share and sold the shares at $18 per share, indicating an insider transaction that may be viewed positively by investors.
• The transactions were made pursuant to a Rule 10b5-1 trading plan, which suggests pre-planned and systematic insider trading activity.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-14

Key Insights

• The reporting person, Francis Lo, exercised a significant number of stock options, including options with exercise prices ranging from $3.99 to $12.14, suggesting confidence in the company's future prospects.
• Lo also sold a large portion (79,590 shares) of the company's common stock, potentially indicating some liquidation of personal holdings.
• The transactions were made pursuant to a Rule 10b5-1 trading plan, which suggests a predetermined strategy and not necessarily a reaction to near-term market conditions.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Current Report Filed: 2026-01-12

Key Insights

• Adaptive Biotechnologies reported its Q4 2025 and full-year 2025 financial results, indicating strong revenue growth and improving profitability.
• The company provided an investor presentation with additional details on its product pipeline, commercial strategy, and long-term growth initiatives.
• No material agreements, leadership changes, or other significant events were disclosed in this 8-K filing.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• Harlan S. Robins, the Chief Scientific Officer of Adaptive Biotechnologies Corp, sold 10,000 shares of the company's common stock on January 6, 2026 at a weighted average price of $16.44 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Robins on August 11, 2025, indicating a pre-planned and systematic approach to the share sale.
• Following the reported transaction, Robins continues to hold a substantial 1,222,312 shares of Adaptive Biotechnologies, suggesting he maintains a significant equity stake in the company.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Current Report Filed: 2025-12-30

Key Insights

• Adaptive Biotechnologies' majority-owned subsidiary Digital Biotechnologies raised up to $15 million in a Series A financing round, demonstrating the company's ability to attract external capital to fund its growth.
• The filing indicates that Adaptive Biotechnologies expects to retain nearly 50% ownership in Digital Biotechnologies after the Series A round, suggesting the parent company will continue to have a significant stake and influence in the subsidiary's operations.
• The company provided forward-looking statements about the completion of the financing and its expected ownership interest, indicating transparency and setting investor expectations around this key corporate development.

Sentiment: Positive Significance: 7/10

View Original Filing →